Expression of cathepsin K and MMP-1 indicate persistent osteodestruktive activity in longstanding ankylosing spondylitis by Neidhart, M et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Expression of cathepsin K and MMP-1 indicate persistent
osteodestruktive activity in longstanding ankylosing spondylitis
Neidhart, M; Baraliakos, X; Seemayer, C; Zelder, C; Gay, R E; Michel, B A; Boehm,
H; Gay, S; Braun, J
Neidhart, M; Baraliakos, X; Seemayer, C; Zelder, C; Gay, R E; Michel, B A; Boehm, H; Gay, S; Braun, J (2008).
Expression of cathepsin K and MMP-1 indicate persistent osteodestruktive activity in longstanding ankylosing
spondylitis. Annals of the Rheumatic Diseases:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Annals of the Rheumatic Diseases 2008, :Epub ahead of print.
Neidhart, M; Baraliakos, X; Seemayer, C; Zelder, C; Gay, R E; Michel, B A; Boehm, H; Gay, S; Braun, J (2008).
Expression of cathepsin K and MMP-1 indicate persistent osteodestruktive activity in longstanding ankylosing
spondylitis. Annals of the Rheumatic Diseases:Epub ahead of print.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Annals of the Rheumatic Diseases 2008, :Epub ahead of print.
Expression of cathepsin K and MMP-1 indicate persistent
osteodestruktive activity in longstanding ankylosing spondylitis
Abstract
BACKGROUND: Ankylosing spondylitis (AS) is a frequent largely genetically determined rheumatic
disease that is characterised by spinal inflammation and new bone formation. However, the exact
pathogenesis including pathology is still not clear. OBJECTIVE: To analyse tissue obtained at spinal
surgery by immunohistochemistry and compare the specimen of patients with AS to those with
degenerative disc disease (DDD). METHODS: Bony and soft tissue specimens of 30 AS and 20 DDD
patients were obtained during spinal osteotomy from different anatomic regions including articular and
spinous processes, interspinous ligaments and intervertebral disks. Immunohistolochemistry was
performed with established markers for cathepsin-K, MMP-1, MMP-3 and RANK-ligand. RESULTS:
Cathepsin-K and MMP-1-positive cells were only observed in AS specimen. Cathepsin-K-positive
multinucleated cells were detected at articular processes adjacent to fibrous tissues. MMP-1 was
expressed in smaller mononuclear cells attached to bone, Invasion of bone by MMP-1 cells was seen at
entheseal sites. In the intervertebral disks, most mononuclear cells were cathepsin-K-positive. Isolated
cells expressing these matrix degrading enzymes found in DDD never showed signs of invasion. No
differences were found for MMP-3 between AS and DDD. Clear expression of RANK ligand was only
detected in one AS patient. CONCLUSION: /B> Cathepsin-K is strongly expressed in different regions
of the spine in AS. Mainly mononuclar cells, fibroblast-like cells, and cells attached to bone and at sites
of bone remodelling expressed cathepsin K suggestive of high osteoclastic activity. This supports the
role of persistent inflammation in the pathogenesis of AS. How these changes relate to
osteoproliferation remains to be determined.
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Abstract 
Background. Ankylosing spondylitis (AS) is a frequent largely genetically determined 
rheumatic disease that is characterised by spinal inflammation and new bone 
formation. However, the exact pathogenesis including pathology is still not clear. 
Objective. To analyse tissue obtained at spinal surgery by immunohistochemistry 
and compare the specimen of patients with AS to those with degenerative disc 
disease (DDD). 
Methods. Bony and soft tissue specimens of 30 AS and 20 DDD patients were 
obtained during spinal osteotomy from different anatomic regions including articular 
and spinous processes, interspinous ligaments and intervertebral disks.  
Immunohistolochemistry was performed with established markers for cathepsin-K, 
MMP-1, MMP-3 and RANK-ligand. 
Results. Cathepsin-K and MMP-1-positive cells were only observed in AS specimen. 
Cathepsin-K-positive multinucleated cells were detected at articular processes 
adjacent to fibrous tissues. MMP-1 was expressed in smaller mononuclear cells 
attached to bone, Invasion of bone by MMP-1 cells was seen at entheseal sites. In 
the intervertebral disks, most mononuclear cells were cathepsin-K-positive. Isolated 
cells expressing these matrix degrading enzymes found in DDD never showed signs 
of invasion. No differences were found for MMP-3 between AS and DDD. Clear 
expression of RANK ligand was only detected in one AS patient. 
Conclusion. Cathepsin-K is strongly expressed in different regions of the spine in AS. 
Mainly mononuclar cells, fibroblast-like cells, and cells attached to bone and at sites 
of bone remodelling expressed cathepsin K suggestive of high osteoclastic activity. 
This supports the role of persistent inflammation in the pathogenesis of AS. How 
these changes relate to osteoproliferation remains to be determined.  
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Introduction 
 
Ankylosing spondylitis (AS), a chronic inflammatory rheumatic disease that affects 
the axial skeleton and other joint and organ structures, causes inflammatory back 
pain in the majority of affected patients as the most characteristic clinical symptom. 
AS leads to structural and functional impairments and a decrease in quality of life in 
many patients (1). Inflammation usually occurs at sites where ligaments and/or 
tendons attach to bone, and this may be followed by bone erosions and/or new bone 
formation at sites of attachment. This is clinically relevant because spinal movement 
of such patients becomes restricted when bone replaces elastic tissues of ligaments 
and tendons. A hallmark of AS are syndesmophytes and ankylosis going along with 
the fusion of vertebrae, apophyseal joints and intervertebral spaces. Syndesmophyte 
formation and progressive ankylosis have been described as a feature of abnormal 
bone remodelling (2), and uncoupling of inflammation and new bone formation have 
been found in an animal model (3). 
The etiology of AS is far from being clear. The genes known to be associated with AS 
such as HLA-B27, ARTS-1, IL-23R and IL-1 account for more than 50% of the total 
risk (4, 5). However, fewer than 10% of HLA-B27-positive individuals in the general 
population become affected (6). Despite the possible triggering of reactive arthritis by 
preceding infections and the association of the spondyloarthritides with HLA-B27 
there is no proven relationship between AS and an inciting infections, and antibiotics 
are ineffective in treating AS (7). The expression of matrix metalloproteinases 
(MMPs) in the synovium and bone of patients with rheumatoid arthritis (RA) and 
osteoarthritis (OA) has been an active area of investigation in the last years (8). In AS 
there are a few recent studies in which these factors have been studied on the serum 
level (9). In two separate cohorts serum levels of MMP-3 were found to correlate with 
disease activity (10, 11). A very recent finding was that MMP-3 levels may even 
predict new bone formation in AS (12). MMP-1 has a predominant role in RA and OA 
because it is rate limiting in the process of collagen degradation (8). Expression of 
both, MMP-1 and MMP-3, has been described in association with inflammatory cells 
present in granulation tissues found in herniated vertebral discs (13). 
Osteoclasts which belong to the monocyte/macrophage family have been identified 
as key players in the osteodestructive process that is frequently observed in RA (2). 
The development of osteoclasts is largely influenced by the action of RANK ligand 
and M-CSF (14). In response to pro-inflammatory cytokines, cathepsin K has been 
made responsible for cartilage destruction mediated by fibroblasts and bone 
resorption by osteoclasts (15).  
Corrective surgery may be indicated when a severe hyperkyphosis of AS leads to an 
unfavourable posture with loss of sagittal balance and loss of horizontal vision. 
Taking advantage of the profound experience of a specialized spine center, we 
analysed biopsy specimens obtained during spinal surgery in AS patients and 
controls concentrating on persistence of spinal inflammation. In this study we show in 
this study that spinal inflammation and osteodestruction are ongoing persistent 
processes in patients with established AS.  
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Material and methods 
 
Patients and samples. Bony and soft tissue specimens from 30 patients with AS 
who underwent surgical intervention of the spine because of hyperkyphosis, with or 
without vertebral “fusion” or spinal instability (“Andersson lesion”) were obtained 
during the surgery from the following sites: 1) articular processes, 2) spinous 
processes with interspinous ligaments and 3) intervertebral disks (Figure 1). The 
histological results were compared with specimens from a group of 20 patients with 
degenerative disk disease (DDD) undergoing spinal surgery for spinal and leg pain. 
Clinical and imaging parameters before and after surgery were analyzed for the 
correlation with the histopathology of the specimens.  
The study was approved by the Ethical Committee of the “Landesärztekammer 
Thüringen” Patients gave informed consent prior to the intervention. They were 
informed that no extra bone material was removed during surgery, only organ tissue 
that was removed anyway because of the intervention was analysed.   
 
Imaging. Conventional standardized radiographs of the thoracic and lumbar spine on 
one film were obtained in the standing position in posterior-anterior and lateral 
projection. In addition detailed views of the cervical, thoracic or lumbar spine region 
of interest were performed in the lateral view and were scored by using the modified 
Stokes AS spinal score (mSASSS, (16)). All images were obtained < 1 month before 
surgery. 
Magnetic resonance imaging sequences were performed according to a standard 
protocol using a spine coil and/or a body-array coil. The MRI techniques administered 
to investigate sacroiliac and spinal inflammation in AS patients have been recently 
described (17). The sagittal view was assessed in the T2-weighted spin-echo 
(SE)/Turbo-SE-Mode sequence (repetition time (TR)/echo time (TE) 4000/108 ms, 
slice thickness 3-4 mm. All MRIs were evaluated by using the ASspiMRI-a Score (18). 
 
Immunohistochemistry. The immunohistological analysis included cathepsin K, 
MMP-1, MMP-3 and RANK ligand as molecules involved in osteodestruction. The 
tissues were fixed in 4% formaldehyde, decalcified using EDTA and NaOH, 
embedded into paraffin, and cut to 0.5 µm sections. Before use, the sections were 
deparaffined with xylol and ethanol. The labelling was performed with the following 
primary antibodies: murine monoclonal antibodies against human cathepsin K (clone 
182-12G5, Chemicon), murine monoclonal antibodies against pro- and active MMP-1 
(clone 36665, R&D), goat polyclonal antibodies against anti human pro- and active 
MMP-3 (AF513, R&D) and murine monoclonal antibodies against RANK ligand 
(TranceODF, clone 12A668, Imgenex). Either purified murine IgG or goat IgG were 
used as negative controls. Secondary antibodies were rabbit anti-mouse IgG HRP-
conjugated or rabbit anti-goat IgG HRP-conjugated (Dako). Staining was performed 
using the EnVision+ System and the Vector VIP substrate kit (Dako).  
 
Statistics. The Wilcoxon signed rank test used for comparing two dependent 
samples. The Mann-Whitney U-test was used to compare the frequency of positive 
staining between AS and DDD considering each site of specimen separately. 
Statistics were performed by dichotomous between patients with positive (score of 
´1´) or negative (´0´) staining to each site of the vertebral body examined. Mann-
Whitney U-test compared the frequency of positive staining between AS and DDD.  
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Results 
 
Patient´s demographics. Overall, 27/30 (90%) AS patients and 7/20 (35%) patients 
from the control group were male. The mean age in the AS group was 62.4±11.6 
years (range 31 – 73 years) and in the control group it was 49.3±10.5 years (range 
44 – 82 years). Finally, the mean disease duration since diagnosis was 5.6±5.7 years 
(range 1-20 years) in the AS group. 
  
Imaging. There was only limited spinal inflammation present in the MRI (mean 
ASspiMRI-a score: 0,3 units), and clearly less when compared to previous studies 
(18), but more radiographic damage (mean mSASSS: 48,5 units), as compared to 
recent cohorts (19). The spinal segment that was most often selected for osteotomy 
was T12/L1.  
 
Immunohistochemistry.  
Cathepsin K-positive multinucleated cells at sites of bone destruction.  
In the sections of tissues from patients with AS, isolated or clustered large, mono- or 
multinucleated cells, were detected to be positive for cathepsin K. Based on their 
morphology, the great majority of these cells could be classified as osteoclasts. In the 
articular processes, numerous cathepsin K positive multinucleated cells were found 
adjacent to fibrous tissues (Figure 2a). In the spinous processes, most cathepsin K-
positive multinucleated cells were accompanied by unstained mononucleated cells, 
possibly fibroblasts or osteoclast precursors (Figure 2b). In the intervertebral disks, a 
large number of mononuclear fibroblast-like cells were found to be positive for 
cathepsin K and to invade into bone (Figure 2c).  
Positive cells for cathepsin K could also be observed in patients with DDD, but they 
were lower frequent (Figures 2d and 3). However, the occurrence of cathepsin K 
positive mononuclear and fibroblast-like cells were highly significantly increased in 
AS, compared to DDD (p<0.001, Figures 3a-b). Cathepsin K-positive multinucleated 
cells were detected in 40-60% of the patients with AS or DDD (Figure 3c), but as 
shown in Figure 2, they were less frequent and active in DDD. These observations 
were reflected by the number of cells attached to bone, which was highly significantly 
increased in AS, compared to DDD (p < 0.001, Figure 3d). Taken these data together, 
cathepsin K positive multinuclear and mononuclear cells appeared actively involved 
in the destruction of bone.  
 
MMP-1 positive mononuclear cells invading bone.  
In the articular processes and intervertebral disks, numerous small mononuclear cells 
attached to bone expressed MMP-1 (Figure 4a, c). Some of these cells appeared to 
be involved in osteodestruction. In the spinous processes with interspinous ligaments, 
such MMP-1 positive cells were identified to invade bone (Figure 4b). Cells 
expressing MMP-1 were observed also in DDD; but they were either isolated or 
clustered and only attached to bone (Figure 4d), but never invading (0/20 patients, 
0%), as it was the case in AS (20/30 patients, 67%, p < 0.001). Moreover, the 
occurrence of MMP-1 positive mononuclear cells was also significantly increased in 
the articular processes of patients with AS, compared to DDD (p < 0.01, Figure 5a).  
The cells expressing MMP-1 invading bone appeared morphologically different from 
those expressing cathepsin K. MMP-1 cannot resorb mineralized bone, but 
presumably the bone had been partially degraded previously by osteoclasts, either 
directly or by releasing molecules capable of breaking down mineralized bone. 
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Positive controls for MMP-1, MMP-3 and cathepsin K were tissue sections of 
rheumatoid arthritis synovial tissues. Strong expressions of MMP-1 and MMP-3 were 
detected, whereas cathepsin K was found in single cells at sites of invasion. In 
contrast to MMP-1 and cathepsin K, no differences in the expression of MMP-3 
between AS and DDD were found. In those patients, MMP-3 was not negative, but 
expressed in mononuclear cells to the same extent in both patient groups (data not 
shown). 
While all patients expressed MMP-3, expression of RANK ligand could only be 
detected in AS patients (Fig. 6, representative example). 
 
 
 
Discussion 
 
This study shows that there is persistence of osteodestruction in patients with 
longstanding AS. Cathepsin K, one of the main collagenolytic proteases produced by 
osteoclasts, is strongly expressed in AS, much more than in DDD examined for 
comparison. In our immunohistochemical analysis, mainly mononuclear cells, 
fibroblast-like cells and cells attached to bone especially at sites of bone remodelling 
showed expression of cathepsin K and MMP-1, suggesting increased occurrence of 
osteclasts. This phenomenon found in spinal biopsy specimens of AS patients 
appeared similar to activated osteoclasts at sites of bone destruction in patients with 
RA (14, 15). In specimen of AS patients obtained at hip replacement recent 
immunohistological data showed that osteoclastic foci and angiogenesis in the 
subchondral bone marrow were increased at sites with remaining cartilage (20). 
However, in AS, new bone formation is much more characteristic for the disease 
process, and it is unclear how inflammation and new bone formation relate. Some 
recent data have even indicated an uncoupling of these processes (2, 3) and anti-
TNF therapy, despite strong clinical efficacy (21), does not seem to have a major 
influence on radiographic progression (22-24). However, the methodology (the 
mSASSS only evaluates the cervical and the lumber spine, and has limited sensitivity 
to change as indicated by a mean change of 1 scoring unit within 2 years), the study 
design (historical cohort) and the power of the trials performed so far have been 
debated. Our data obtained from patients without recent anti-TNF therapy indicate 
that inflammation and osteodestruction persist in AS patients with much radiographic 
damage. This is also in line with the recent observation that MMP-3 levels of patients 
with AS predict radiographic damage (12). This may indicate a role for these features 
also for new bone formation. It is, however, still not clear how these processes are 
linked.  
Possibly, systemic triggers are involved in the activation and/or differentiation of 
osteoclasts in AS. We detected RANK ligand in the spinous process of at least one 
AS patient. This is consistent with recent data showing that serum levels of RANK 
ligand are upregulated in patients with AS – in possible relationship with bone 
mineral density and radiological changes (25).  
Taken together, these data suggest that de novo generation of osteoclasts is 
involved in the ongoing pathological process in AS. 
 
In the early stage of inflammatory rheumatic diseases, it is believed that matrix 
degrading enzymes play an important role (26). Our data demonstrate numerous foci 
of active bone destruction at the site of the surgical intervention which is chosen for 
static reasons. These data are in line with a previous study (27), based on 
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biochemical markers, which showed that bone turnover in patients with AS reflects 
normal osteoblastic activity, but high osteoclastic activity. An interesting observation 
of our study is that MMP-3 was almost not detected in the biopsy specimen examined. 
Since our stainings included both pro- and active MMPs and since all patients 
expressed MMP-3, this was not a problem of sensitivity, but could be due to the fact 
that the intensity of expression in immunohistochemistry is more qualitative than 
quantitative. In contrast, ELISAs of biological fluids such as serum are better to 
provide quantitative data. Indeed, recent data have suggested that MMP-3 serum 
levels correlate with disease activity (10, 11). Furthermore, elevated MMP-3 levels in 
the periphery could potentially well derive from other sources such as circulating 
monocytes.  
There is no straightforward explanation for this discrepancy, it, however, seems 
possible that the study populations were different in terms of disease duration (almost 
30 years in our patients).   
It seems likely that persistent inflammation and osteodestruction is responsible for 
the continuous pain reported by patients with AS (28) but this has not been proven to 
date. In a recent study (20) there was some correlation between inflammatory 
changes seen by MRI and cellular inflammation detected by immunohistology in 
specimen that were also obtained during osteotomy of AS patients. However, there is 
also some but limited evidence for a dissociation between spinal inflammation as 
detected by MRI and clinical symptoms in some AS patients (Braun J, personal 
communication).  
 
Our observations may have implications for the treatment of AS patients. On the one 
hand, it has been shown that the bisphosphonate pamidronate which has anti-
osteoclast activity, improves the disease activity of patients with AS (29). It is 
unknown whether there is an influence of bisphosphonates on radiographic damage 
but it seems likely that the osteoporosis and osteopenia found in 20-50% of AS 
patients (30) will improve by this treatment.. On the other hand, TNF-α blockers have 
been clearly shown to improve the clinical symptoms (21) and the spinal inflammation 
as detected by MRI (31, 32) of AS patients. However, their effect on new bone 
formation may be limited (see above). This may be different for continuous therapy 
with NSAIDs (33). In consequence, studies should be performed to combine such 
approaches. For ethical reasons, it will be diffcult to prove the effects of therapy by 
immunohistology. 
In conclusion, unlike other proteases, cathepsin K - one of the main collagenolytic 
protease in osteoclasts - is significantly stronger expressed in patients with AS, as 
compared to DDD. Mainly mononuclear cells, fibroblast-like cells and cells attached 
to bone and at sites of bone destruction express cathepsin K, reflecting high 
osteoclastic activity in those regions. RANK ligands could be involved in the 
generation of osteoclasts. Our data support the view that cells expressing cathepsin 
K or MMP-1 play an important role in the pathogenesis of AS, which is not only 
characterized by osteoproliferation, but also by inflammation and ongoing 
osteodestruction of bone. 
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Figure legends 
 
Figure 1: Magnetic resonance image of the transversal section of the spine used for 
clarification  of the localisation of the histological specimens taken in this study. 
 
Figures 2: a-c, Immunohistochemical examination for cathepsin K in patients with 
ankylosing spondylitis (AS); d, Intervertebral disk of a patient with degenerative disk 
disease (DDD). AP=articular process, SP=spinous process, ID=intervertebral disk. 
 
Figures 3: a/b, Percentage of AS and DDD patients with positive cathepsin K cells at 
different sites of the vertebra. AP=articular process, SP=spinous process, 
ID=intervertebral disk. The occurrence of cathepsin K positive cells is higher in AS 
compared with DDD at all sites examined in this study. 
 
Figures 4: a-c, Immunhistochemical examination for MMP-1 in patients with 
ankylosing spondylitis (AS); d, Intervertebral disk of a patient with degenerative disk 
disease (DDD). AP=articular process, SP=spinous process, ID=intervertebral disk. 
 
Figures 5 a/b, Percentage of AS and DDD patients with positive MMP-1 cells at 
different sites of the vertebra. AP=articular process, SP=spinous process, 
ID=intervertebral disk. The occurrence of MMP-1 positive cells is higher in AS 
compared with DDD particularly in the AP.  
 
Figures 6a/b. Expression of RANK ligand in the spinous process in a patient with 
ankylosing spondylitis (AS) and a patient with degenerative disk disease (DDD). 
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